KRONOS BIO INC. - COM

Kronos Bio Announces Restructuring to Focus Resources on Clinical Development with Extended Cash Runway

07 Mar 2024 16:05:00 By Nasdaq GlobeNewswire

Kronos Bio To Present Three Posters at AACR 2024 Annual Meeting

05 Mar 2024 16:44:11 By Nasdaq GlobeNewswire

Kronos Bio Announces Participation in 44th Annual Cowen Health Care Conference

27 Feb 2024 16:05:00 By Nasdaq GlobeNewswire

Kronos Bio Implements New Leadership Structure to Drive Pipeline Advancement

25 Jan 2024 08:00:00 By Nasdaq GlobeNewswire

Kronos Bio Announces Pipeline Update and p300 KAT Inhibitor Development Candidate

18 Dec 2023 16:06:03 By Nasdaq GlobeNewswire

Kronos Bio Announces Participation in H.C. Wainwright 4th Annual Precision Oncology Virtual Conference

04 Dec 2023 08:00:00 By Nasdaq GlobeNewswire

Kronos Bio Announces Participation in 35th Annual Piper Sandler Healthcare Conference

27 Nov 2023 16:05:00 By Nasdaq GlobeNewswire

Kronos Bio Reports Recent Business Progress and Third-Quarter 2023 Financial Results

13 Nov 2023 16:05:00 By Nasdaq GlobeNewswire

Kronos Bio Announces Plan to Optimize Resource Allocation, Restructure and Contain Costs Following Positive Preliminary Clinical Data from its KB-0742 Phase 1/2 Study

02 Nov 2023 16:05:00 By Nasdaq GlobeNewswire

Kronos Bio Presents Positive Preliminary Data from the Phase 1 Dose Escalation Portion of the Ongoing Phase 1/2 KB-0742 Study at the Connective Tissue Oncology Society Annual Meeting

02 Nov 2023 12:00:00 By Nasdaq GlobeNewswire

Kronos Bio To Present Positive Preliminary Data from Phase 1 Dose Escalation Portion of Ongoing Phase 1/2 KB-0742 Study at the Connective Tissue Oncology Society Annual Meeting

27 Oct 2023 08:00:00 By Nasdaq GlobeNewswire

Kronos Bio Presents Positive Preliminary Data from Phase 1 Dose Escalation Portion of Phase 1/2 KB-0742 Study at AACR-NCI-EORTC

13 Oct 2023 12:30:00 By Nasdaq GlobeNewswire

Kronos Bio To Present Interim Data from Phase 1 Dose Escalation Portion of Ongoing Phase 1/2 KB-0742 Study at AACR-NCI-EORTC and Host Virtual Investor Event on October 13

04 Oct 2023 16:05:00 By Nasdaq GlobeNewswire

Kronos Bio Announces Departure of Chief Financial Officer and Head of Corporate Development

17 Aug 2023 08:00:00 By Nasdaq GlobeNewswire

Kronos Bio Reports Recent Business Progress and Second-Quarter 2023 Financial Results

08 Aug 2023 16:05:03 By Nasdaq GlobeNewswire

Kronos Bio Names Marc Besman, Ph.D., as Senior Vice President of Regulatory Affairs and Clinical Quality Assurance

06 Jun 2023 08:00:01 By Nasdaq GlobeNewswire

Kronos Bio Announces Participation in Upcoming Investor Conferences

01 Jun 2023 16:05:00 By Nasdaq GlobeNewswire

Kronos Bio Reports Recent Business Progress and First-Quarter 2023 Financial Results

10 May 2023 16:05:02 By Nasdaq GlobeNewswire

Kronos Bio Appoints Roger Dansey, M.D., to Board of Directors

24 Apr 2023 16:05:00 By Nasdaq GlobeNewswire

Kronos Bio Announces Changes to Board of Directors

11 Apr 2023 16:05:00 By Nasdaq GlobeNewswire